U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545954) titled 'DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer' on April 15.
Brief Summary: This is a single center pilot, phase Ib study with a safety lead-in evaluating the safety and preliminary efficacy of the EBP inhibitor DSP-0390 in combination with atezolizumab in patients with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after initial induction therapy with platinum-based chemotherapy and anti-PD-L1 immunotherapy (atezolizumab or durvalumab per treating physician's discretion). This trial is testing the hypothesis that inhibition of de novo cholesterol synthesis by DSP-0390 when u...